Patient attitudes and understanding about biosimilars: an international cross-sectional survey

To understand the levels of awareness, usage, and knowledge of biosimilars among patients, caregivers, and the general population in the US and the European Union; perceptions of biosimilars compared to originator biologics; perceived benefits and drawbacks of clinical trials; and whether advocacy g...

Full description

Saved in:
Bibliographic Details
Published in:Patient preference and adherence 2016-01, Vol.10 (Issue 1), p.937-948
Main Authors: Jacobs, Ira, Singh, Ena, Sewell, K Lea, Al-Sabbagh, Ahmad, Shane, Lesley G
Format: Article
Language:English
Subjects:
advocacy groups
Arthritis
biologic therapy
biosimilar
Breast cancer
Cancer
Caregivers
Clinical trials
Colitis
Colorectal cancer
Comparative analysis
Diseases
Education
Health education
inflammatory disease
Lung cancer
oncology
Original Research
patient attitude
patient understanding
Pharmaceutical industry
Psoriasis
Public opinion
Retirement benefits
Rheumatoid factor
Surveys
Tumors
Ulcerative colitis
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To understand the levels of awareness, usage, and knowledge of biosimilars among patients, caregivers, and the general population in the US and the European Union; perceptions of biosimilars compared to originator biologics; perceived benefits and drawbacks of clinical trials; and whether advocacy groups impact patients' willingness to try a biosimilar. An international survey was conducted which contained up to 56 closed-ended (requiring yes/no or ranking answers) and open-ended questions, depending on the population assigned. The survey was divided into distinct sections, including medication-class awareness, usage, and knowledge about biologic and biosimilar therapies; perceptions of clinical trials; and involvement in advocacy groups. Interviews were conducted in adults categorized as: 1) diagnosed: patients with inflammatory bowel disease including Crohn's disease and ulcerative colitis, rheumatoid arthritis, psoriasis, breast cancer, lung cancer, colorectal cancer, or non-Hodgkin's lymphoma; 2) diagnosed advocacy: individuals with these diseases who participated in patient support groups; 3) caregiver: has a loved one with these conditions and is involved in medical decisions; 4) general population: aged 18-64 years, without these conditions. Statistical analyses among groups within a region (US or EU) used column proportions test with a 95% confidence interval. In all, 3,198 individuals responded. Awareness about biologic therapies was significantly higher in diagnosed, diagnosed advocacy, and caregiver groups (45%-78%) versus general population (27%; P
ISSN:1177-889X
1177-889X
DOI:10.2147/PPA.S104891